OR04 Endocrine Disrupting Chemicals

Program: Abstracts - Orals, Poster Previews, and Posters
Oral Session
Endocrine Disruptors-Basic
Friday, April 1, 2016: 11:45 AM-1:15 PM
Room 258 (BCEC)
Barbara Demeneix, PHD, DSC, Muséum National d'Histoire Naturelle, Paris CEDEX 05, France and To Be Determined

BD: Founder, Watchfrog. Disclosure Not Provided: RTZ, BR
11:45 AM
Lucia Speroni, PhD1, Maria Voutilainen2, Marja L Mikkola2, Skylar A Klager1, Cheryl M Schaeberle1, Carlos Sonnenschein, MD1 and Ana M Soto, MD1, (1)Integrative Physiology & Pathobiology, Tufts University, Boston, MA
(2)Developmental Biology Program, Institute of Biotechnology, University of Helsinki, Helsinki, Finland
12:00 PM
Ana Cheong1, Xiang Zhang1, Yuk-Yin Cheung1, Jing Chen1, Mario Medvedovic, PhD1, Gail S. Prins, PhD2 and Shuk-Mei Ho, PhD1, (1)Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH
(2)Dept of Urology, University of Illinois-Chicago, Chicago, IL
12:15 PM
Sheryl E Arambula1, Scott M Belcher, PhD2, Stephen D Turner, PhD3, Keith L Gonzales, PhD4 and Heather B Patisaul, PhD1, (1)Biological Sciences, North Carolina State University, Raleigh, NC
(2)Pharmacology & Cell Biophysics, University of Cincinnati, Cincinnati, OH
(3)Public Health Science, University of Virginia School of Medicine, Charlottesville, VA
(4)Stirplate.io, Stirplate Inc., New York, NY
12:30 PM
Shannon D. Whirledge, PhD, Laboratory of Signal Transduction, NIEHS, Durham, NC, Matthew Quinn, PhD, Signal Transduction Laboratory, NIEHS, RTP, NC and John A Cidlowski, PhD, Signal Transduction Laboratory, NIEHS/NIH, Durham, NC
12:45 PM
Lindsey S. Treviño, Ph.D.1, Charles E Foulds, Ph.D.2, Philip F Lavere, BS2, Jun Qin, PhD3, Bert W O'Malley, M.D.2 and Cheryl Lyn Walker, Ph.D.1, (1)Center for Translational Cancer Research, Texas A&M Health Science Center, Houston, TX
(2)Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX
(3)Department of Molecular and Cellular Biology; Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX
1:00 PM
Sören Verstraete, MD1, Ilse Vanhorebeek, MEng, PhD2, Adrian Covaci, PhD3, Fabian Güiza, PhD1, Govindan Malarvannan, PhD3, Philippe G Jorens, MD, PhD4 and Greet Van den Berghe, MD, PhD1, (1)Laboratory and Clinical Department of Intensive Care Medicine, Katholieke Universiteit Leuven, Leuven, Belgium
(2)Clinical Division and Laboratory of Intensive Care Medicine, KU Leuven, Leuven, Belgium
(3)Toxicology Center, University of Antwerp, Antwerp, Belgium
(4)Critical Care Medicine, Antwerp University Hospital, Edegem, Belgium


The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire